Glucose Dependence of Glycogen Synthase Activity Regulation by GSK3 and MEK/ERK Inhibitors and Angiotensin-(1-7) Action on These Pathways in Cultured Human Myotubes
Overview
Authors
Affiliations
Glycogen synthase (GS) is activated by glucose/glycogen depletion in skeletal muscle cells, but the contributing signaling pathways, including the chief GS regulator GSK3, have not been fully defined. The MEK/ERK pathway is known to regulate GSK3 and respond to glucose. The aim of this study was to elucidate the GSK3 and MEK/ERK pathway contribution to GS activation by glucose deprivation in cultured human myotubes. Moreover, we tested the glucose-dependence of GSK3 and MEK/ERK effects on GS and angiotensin (1-7) actions on these pathways. We show that glucose deprivation activated GS, but did not change phospho-GS (Ser640/1), GSK3β activity or activity-activating phosphorylation of ERK1/2. We then treated glucose-replete and -depleted cells with SB415286, U0126, LY294 and rapamycin to inhibit GSK3, MEK1/2, PI3K and mTOR, respectively. SB415286 activated GS and decreased the relative phospho-GS (Ser640/1) level, more in glucose-depleted than -replete cells. U0126 activated GS and reduced the phospho-GS (Ser640/1) content significantly in glucose-depleted cells, while GSK3β activity tended to increase. LY294 inactivated GS in glucose-depleted cells only, without affecting relative phospho-GS (Ser640/1) level. Rapamycin had no effect on GS activation. Angiotensin-(1-7) raised phospho-ERK1/2 but not phospho-GSK3β (Ser9) content, while it inactivated GS and increased GS phosphorylation on Ser640/1, in glucose-replete cells. In glucose-depleted cells, angiotensin-(1-7) effects on ERK1/2 and GS were reverted, while relative phospho-GSK3β (Ser9) content decreased. In conclusion, activation of GS by glucose deprivation is not due to GS Ser640/1 dephosphorylation, GSK3β or ERK1/2 regulation in cultured myotubes. However, glucose depletion enhances GS activation/Ser640/1 dephosphorylation due to both GSK3 and MEK/ERK inhibition. Angiotensin-(1-7) inactivates GS in glucose-replete cells in association with ERK1/2 activation, not with GSK3 regulation, and glucose deprivation reverts both hormone effects. Thus, the ERK1/2 pathway negatively regulates GS activity in myotubes, without involving GSK3 regulation, and as a function of the presence of glucose.
Signaling pathways and intervention for therapy of type 2 diabetes mellitus.
Cao R, Tian H, Zhang Y, Liu G, Xu H, Rao G MedComm (2020). 2023; 4(3):e283.
PMID: 37303813 PMC: 10248034. DOI: 10.1002/mco2.283.
PET molecular imaging for pathophysiological visualization in Alzheimer's disease.
Wang J, Jin C, Zhou J, Zhou R, Tian M, Lee H Eur J Nucl Med Mol Imaging. 2022; 50(3):765-783.
PMID: 36372804 PMC: 9852140. DOI: 10.1007/s00259-022-05999-z.
Rizk M, Saker Z, Harati H, Fares Y, Bahmad H, Nabha S Mol Biol Rep. 2021; 48(3):2669-2686.
PMID: 33650079 DOI: 10.1007/s11033-021-06237-9.
Impact of Conventional and Atypical MAPKs on the Development of Metabolic Diseases.
Kassouf T, Sumara G Biomolecules. 2020; 10(9).
PMID: 32872540 PMC: 7563211. DOI: 10.3390/biom10091256.
Antioxidative and Hypoglycemic Effect of Ta-ermi Extracts on Streptozotocin-Induced Diabetes.
Jing S, Zhao Z, Wu J, Yan L Diabetes Metab Syndr Obes. 2020; 13:2147-2155.
PMID: 32606873 PMC: 7320996. DOI: 10.2147/DMSO.S258116.